Anti-(human Progrowth Differentiation Factor 8) (human Monoclonal Srk-015 .gamma.4-chain) Uses, Dosage, Side Effects and more
Anti-(human Progrowth Differentiation Factor 8) (human Monoclonal Srk-015 .gamma.4-chain) is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy).
| Trade Name | Anti-(human Progrowth Differentiation Factor 8) (human Monoclonal Srk-015 .gamma.4-chain) |
| Generic | Apitegromab |
| Apitegromab Other Names | Apitegromab, Immunoglobulin g4 (234-proline), anti-(human progrowth differentiation factor 8) (human monoclonal srk-015 .gamma.4-chain), disulfide with human monoclonal srk-015 .lambda.-chain, dimer |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
